Profiles

Adele Holloway

Dr Adele Holloway

Adele Holloway

Associate Head, Learning and Teaching

Room 337a , Medical Science 2 (MS2)

+61 3 6226 2670 (phone)

A.F.Holloway@utas.edu.au

Genes contain the instructions that tell our cells which proteins to manufacture. These proteins, in turn, are the building blocks of our body and they regulate the processes that allow us to sense our environment and respond to it, digest food, fight off diseases, grow, reproduce and carry out the range of other functions that are essential to our survival.

Our knowledge of genes has grown considerably in recent years, especially with major research initiatives like the Human Genome Project. We now know much more about the range of genes, what they do, how they vary from person to person, and what role they play in disease. An area of growing interest, however, is the process by which the genes themselves are regulated.

Dr Adele Holloway, Senior Lecturer in the School of Medicine, investigates the role of transcription factors and epigenetic mechanisms in the regulation of gene expression. Transcription factors are proteins that act like switches, increasing or decreasing the expression of particular genes. Epigenetic mechanisms are processes that modify the chemistry or structure of the DNA that makes up genes.

‘Genes are like the notes in a musical score,’ Dr Holloway says. ‘But equally important are the instructions that tell the musician how fast or how slow to play, when to pause, and how to coordinate with the other musicians.’

The role of transcription factors and epigenetic mechanisms in making sure the right genes are switched on or off at the right time is vital for the normal behaviour of cells, and therefore for our health. A focus of Dr Holloway’s work is to understand how this process can go wrong in some diseases, especially in cancer.

Cancer is a disease in which the normal regulation of a cell is disrupted, allowing it to divide and multiply in an uncontrolled way. Dr Holloway is currently studying prostate cancer and leukaemia and, in particular, the role of transcription factors and epigenetic mechanisms in causing cancerous cells to become metastatic, that is to spread to different parts of the body.

‘By better understanding these changes, we might be able to develop better diagnostic methods and treatments. Ultimately, we hope to be able to intervene to stop cancers from becoming metastatic.’

Dr Holloway’s team uses computational biology to do genome-wide analyses and molecular biology techniques to look at the role of individual genes. ‘What we are finding is that the more we know, the more we appreciate the level of complexity. Gene regulation is an incredibly intricate process.’

Dr Holloway is also passionate about the teaching of research skills. As the Associate Head of Learning and Teaching at the School of Medicine, she is currently investigating how research skills are taught and how the curriculum can be improved across various disciplines. By surveying students, getting their feedback, and analysing responses, she aims to get a better understanding of the skills students are acquiring and how this matches up with expectations.

‘Good research skills are important not just to research scientists but also for a range of professionals like paramedics, pharmacists, and medical graduates,’ Dr Holloway says. ‘Having the skills to understand research, how it is done and what the results mean is central to making good evidence-based judgements and keeping up with best practice in their fields.’

Dr Holloway is a molecular biologist in the School of Medicine, Faculty of Health with a research interest in gene regulation and epigenetics.

Biography

Before joining the University of Tasmania, Dr Holloway was a Postdoctoral Research Fellow at the Hanson Centre for Cancer Research (Adelaide) and at the John Curtin School of Medical Research, ANU (Canberra).

Career summary

Qualifications

PhD, University of Tasmania, Australia. 1997
BSc (1st Class Hons), University of Tasmania, Australia. 1992

Memberships

Professional practice

Dr Holloway is a member of the Australian Society for Medical Research and the Australian Epigenetic Alliance.

Teaching

molecular biology, biochemistry

Teaching expertise

Dr Holloway is co-ordinator of the Bachelor of Medical Research. She has expertise in the areas of undergraduate biochemistry and molecular biology teaching, and as a supervisor of both Honours and PhD students.

Teaching responsibility

Research Appointments

NHMRC Career Development Fellowship Panel (2014-2015)
Conference Chair Australian Epigenetics Alliance Conference (2015)
Australian Epigenetic Alliance, State Representative
NHMRC Grant Review Panel (2006-7, 2010-12)
Lorne Genome Conference Organising committee (2011-2013)
AMATA Conference Organising committee (2010)
ASMR Tasmanian Medical Research Week Committee (2007-2010, 2014- present)

View more on Professor Adele Holloway in WARP

Expertise

regulation of gene expression
epigenetic mechanisms
cancer gene regulation
cancer biology
immune regulation

Research Themes

Dr Holloway's research aligns to the University's research theme of Better Health. Her research interests are focused on understanding how genes are regulated in response to cellular signals, with a particular interest in the immune system.

This work is investigating the role of transcription factors and epigenetic mechanisms in the regulation of gene expression. She is also conducting research aimed at understanding how disruption of normal gene expression programs contributes to the development and progression of disease such as cancer, with a particular focus on leukaemia and prostate cancer.

Collaboration

Dr Holloway collaborates with a number of fellow researchers within the University of Tasmania as well as inter state.

Assoc Prof Joanne Dickinson, Menzies Institute for Medical Research, University of Tasmania
Dr Kate Brettingham-Moore, School of Medicine, University of Tasmania
Dr Jac Charlesworth, Menzies Institute for Medical Research, University of Tasmania
Assoc Prof Sudha Rao, University of Canberra, ACT
Dr Phillippa Taberlay, Garvan Institute for Medical Research, NSW

Current projects

Role of RUNX transcription factors in leukaemia and other cancers
Transcriptional and epigenetic regulation of gene expression prostate cancer
Inherited determinants of epigenetic profiles and their role in cancer development
Regulation of gene expression in the immune system

Fields of Research

Biochemistry and cell biology (310199)
Epigenetics (incl. genome methylation and epigenomics) (310504)
Cancer genetics (321103)
Cancer cell biology (321101)
Molecular targets (321108)
Gene expression (incl. microarray and other genome-wide approaches) (310505)
Cell metabolism (310103)
Genome structure and regulation (310508)
Medical genetics (excl. cancer genetics) (320213)
Oncology and carcinogenesis (321199)
Central nervous system (320903)
Respiratory diseases (320103)
Epidemiology (420299)
Educational technology and computing (390405)
Cellular immunology (320404)
Cellular nervous system (320902)
Immunology (320499)
Solid tumours (321111)
Health services and systems (420399)
Basic pharmacology (321401)
Cell development, proliferation and death (310102)
Genetics (310599)
Haematology (320102)
Tumour immunology (320409)
Clinical sciences (320299)
Sensory systems (320907)
Other biological sciences (319999)
Ophthalmology (321201)
Analytical biochemistry (310101)
Medicine, nursing and health curriculum and pedagogy (390110)
Education assessment and evaluation (390402)
Genomics (310509)
Radiation therapy (321110)
Preventative health care (420605)
Anaesthesiology (320201)
Cancer diagnosis (321102)
Medical biochemistry and metabolomics (320599)
Medical bacteriology (320701)
Bioinformatic methods development (310201)
Cellular interactions (incl. adhesion, matrix, cell wall) (310105)
Cardiology (incl. cardiovascular diseases) (320101)
Cancer therapy (excl. chemotherapy and radiation therapy) (321104)
Haematological tumours (321106)
Aboriginal and Torres Strait Islander public health and wellbeing (450417)

Research Objectives

Clinical health (200199)
Expanding knowledge in the environmental sciences (280111)
Expanding knowledge in the biological sciences (280102)
Expanding knowledge in the health sciences (280112)
Diagnosis of human diseases and conditions (200101)
Disease distribution and transmission (incl. surveillance and response) (200404)
Treatment of human diseases and conditions (200105)
Teaching and instruction technologies (160304)
Men's health (200504)
Expanding knowledge in the biomedical and clinical sciences (280103)
Learner and learning (160199)
Prevention of human diseases and conditions (200104)
Assessment, development and evaluation of curriculum (160301)
Expanding knowledge in the physical sciences (280120)
Human pharmaceutical products (240899)
Efficacy of medications (200102)

Publications

Dr Holloway's research has made significant contributions to our understanding of regulation of gene expression by transcription factors and chromatin. Her current research in this area continues a track record in the field which has been published in highly regarded journals in the Biochemistry and Molecular Biology Field, including Journal of Biological Chemistry, Journal of Experimental Medicine,Nucleic Acids Research and Molecular and Cellular Biology. She has also more recently made important contributions to our understanding of transcription factor driven and epigenetic regulation of gene expression in cancer.

Total publications

Highlighted publications

(5 outputs)

Year	Type	Citation
2005	Journal Article	Brettingham-Moore KH, Rao S, Jeulich T, Shannon MF, Holloway AF, 'GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements', Nucleic Acids Research, 33, (1) pp. 225-234. ISSN 0305-1048 (2005) [Refereed Article] DOI: 10.1093/nar/gki161 [eCite] [Details] Citations: Scopus - 31Web of Science - 28 Co-authors: Brettingham-Moore KH Tweet
2004	Journal Article	Henderson A, Holloway AF, Reeves R, Tremethick DJ, 'Recruitment of SW1/SNF to the human immunodeficiency virus type 1 promotor', Molecular and Cellular Biology, 24, (1) pp. 389-397. ISSN 0270-7306 (2004) [Refereed Article] DOI: 10.1128/MCB.24.1.389-397.2004 [eCite] [Details] Citations: Scopus - 68Web of Science - 62 Tweet
2003	Journal Article	Holloway AF, Rao S, Chen X, Shannon MF, 'Changes in chromatin accessibility across the GM-CSF promoter upon T cell activation are dependent on nuclear factor kappaB proteins', Journal of Experimental Medicine, 197, (4) pp. 413-423. ISSN 0022-1007 (2003) [Refereed Article] DOI: 10.1084/jem.20021039 [eCite] [Details] Citations: Scopus - 63Web of Science - 61 Tweet
2002	Journal Article	Holloway AF, Rao S, Shannon MF, 'Regulation of cytokine gene transcription in the immune system', Molecular Immunology, 38, (8) pp. 567-580. ISSN 0161-5890 (2002) [Refereed Article] DOI: 10.1016/S0161-5890(01)00094-3 [eCite] [Details] Citations: Scopus - 54Web of Science - 48 Tweet
2000	Journal Article	Holloway AF, Occhiodoro F, Mittler G, Meisterernst MF, Shannon MF, 'Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells', Journal of Biological Chemistry, 275, (28) pp. 21668-21677. ISSN 0021-9258 (2000) [Refereed Article] DOI: 10.1074/jbc.M909058199 [eCite] [Details] Citations: Scopus - 18Web of Science - 19 Tweet

Journal Article

(37 outputs)

Year	Citation	Altmetrics
2022	Verhoeff TF, Holloway AF, Dickinson JL, 'Non-coding RNA regulation of integrins and their potential as therapeutic targets in cancer', Cellular Oncology pp. 1-12. ISSN 2211-3436 (2022) [Refereed Article] DOI: 10.1007/s13402-022-00752-y [eCite] [Details] Citations: Web of Science - 2 Co-authors: Verhoeff TF; Dickinson JL Tweet
2022	Verhoeff TJ, Holloway AF, Dickinson JL, 'A novel long non‑coding RNA regulates the integrin, ITGA2 in breast cancer', Breast Cancer Research and Treatment, 192 pp. 89-100. ISSN 0167-6806 (2022) [Refereed Article] DOI: 10.1007/s10549-021-06496-x [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Verhoeff TJ; Dickinson JL Tweet
2021	Wilson A, Howitt S, Holloway A, Williams A-M, Higgins D, 'Factors affecting paramedicine students' learning about evidence-based practice: a phenomenographic study', BMC Medical Education, 21, (1) pp. 1-12. ISSN 1472-6920 (2021) [Refereed Article] DOI: 10.1186/s12909-021-02490-5 [eCite] [Details] Citations: Web of Science - 1 Co-authors: Williams A-M Tweet
2020	Wilkinson EJ, Woodworth AM, Parker M, Phillips JL, Malley RC, et al., 'Epigenetic regulation of the ITGB4 gene in prostate cancer', Experimental Cell Research, 392, (2) pp. 1-10. ISSN 0014-4827 (2020) [Refereed Article] DOI: 10.1016/j.yexcr.2020.112055 [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Wilkinson EJ; Woodworth AM; Parker M; Phillips JL; Malley RC; Dickinson JL Tweet
2019	Sutton LP, Jeffreys SA, Phillips JL, Taberlay PC, Holloway AF, et al., 'DNA methylation changes following DNA damage in prostate cancer cells', Epigenetics, 14, (10) pp. 989-1002. ISSN 1559-2294 (2019) [Refereed Article] DOI: 10.1080/15592294.2019.1629231 [eCite] [Details] Citations: Scopus - 16Web of Science - 13 Co-authors: Sutton LP; Jeffreys SA; Phillips JL; Taberlay PC; Ambrose M; Young A; Berry R; Brettingham-Moore KH Tweet
2018	De Paoli-Iseppi R, Prentice L, Marthick JR, Thomson R, Holloway AF, et al., 'Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation', Pathology, 50, (6) pp. 622-628. ISSN 0031-3025 (2018) [Refereed Article] DOI: 10.1016/j.pathol.2018.05.006 [eCite] [Details] Citations: Scopus - 3Web of Science - 5 Co-authors: De Paoli-Iseppi R; Prentice L; Marthick JR; Thomson R; Dickinson JL; Burgess J Tweet
2018	Phillips JL, Taberlay PC, Woodworth AM, Hardy K, Brettingham-Moore KH, et al., 'Distinct mechanisms of regulation of the ITGA6 and ITGB4 genes by RUNX1 in myeloid cells', Journal of Cellular Physiology, 233, (4) pp. 3439-3453. ISSN 0021-9541 (2018) [Refereed Article] DOI: 10.1002/jcp.26197 [eCite] [Details] Citations: Scopus - 10Web of Science - 10 Co-authors: Phillips JL; Taberlay PC; Woodworth AM; Brettingham-Moore KH; Dickinson JL Tweet
2017	Woodworth AM, Holloway AF, 'The role of epigenetic regulation in transcriptional memory in the immune system', Advances in Protein Chemistry and Structural Biology, 106 pp. 43-69. ISSN 1876-1623 (2017) [Refereed Article] DOI: 10.1016/bs.apcsb.2016.09.002 [eCite] [Details] Citations: Scopus - 12Web of Science - 11 Co-authors: Woodworth AM Tweet
2016	Atashrazm F, Lowenthal RM, Dickinson JL, Holloway AF, Woods GM, 'Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo', OncoTarget, 7, (29) pp. 46028-46041. ISSN 1949-2553 (2016) [Refereed Article] DOI: 10.18632/oncotarget.10016 [eCite] [Details] Citations: Scopus - 16Web of Science - 13 Co-authors: Lowenthal RM; Dickinson JL; Woods GM Tweet
2016	Cazaly E, Thomson R, Marthick JR, Holloway AF, Charlesworth J, et al., 'Comparison of pre-processing methodologies for Illumina 450k methylation array data in familial analyses', Clinical Epigenetics, 8, (1) Article 75. ISSN 1868-7083 (2016) [Refereed Article] DOI: 10.1186/s13148-016-0241-2 [eCite] [Details] Citations: Scopus - 9Web of Science - 6 Co-authors: Cazaly E; Thomson R; Marthick JR; Charlesworth J; Dickinson JL Tweet
2015	Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Dickinson JL, 'Fucoidan and cancer: a multifunctional molecule with anti-tumor potential', Marine Drugs, 13, (4) pp. 2327-2346. ISSN 1660-3397 (2015) [Refereed Article] DOI: 10.3390/md13042327 [eCite] [Details] Citations: Scopus - 197Web of Science - 184 Co-authors: Lowenthal RM; Woods GM; Dickinson JL Tweet
2015	Atashrazm F, Lowenthal RM, Woods GM, Holloway AF, Karpiniec SS, et al., 'Fucoidan suppresses the growth of human acute promyelocytic leukemia cells in vitro and in vivo', Journal of Cellular Physiology, 231, (3) pp. 688-697. ISSN 0021-9541 (2015) [Refereed Article] DOI: 10.1002/jcp.25119 [eCite] [Details] Citations: Scopus - 31Web of Science - 30 Co-authors: Lowenthal RM; Woods GM; Dickinson JL Tweet
2015	Brettingham-Moore KH, Taberlay PC, Holloway AF, 'Interplay between transcription factors and the epigenome: insight from the role of RUNX1 in leukemia', Frontiers in Immunology, 6 Article 499. ISSN 1664-3224 (2015) [Refereed Article] DOI: 10.3389/fimmu.2015.00499 [eCite] [Details] Citations: Scopus - 22Web of Science - 21 Co-authors: Brettingham-Moore KH; Taberlay PC Tweet
2015	Cazaly E, Charlesworth J, Dickinson JL, Holloway AF, 'Genetic determinants of epigenetic patterns: providing insight into disease', Molecular Medicine, 21 pp. 400-409. ISSN 1076-1551 (2015) [Refereed Article] DOI: 10.2119/molmed.2015.00001 [eCite] [Details] Citations: Scopus - 8Web of Science - 8 Co-authors: Cazaly E; Charlesworth J; Dickinson JL Tweet
2015	Chin PS, Marthick JR, West AC, Short AK, Chuckowree J, et al., 'Regulation of the ITGA2 gene by epigenetic mechanisms in prostate cancer', The Prostate, 75, (7) pp. 723-734. ISSN 0270-4137 (2015) [Refereed Article] DOI: 10.1002/pros.22954 [eCite] [Details] Citations: Scopus - 22Web of Science - 22 Co-authors: Chin PS; Marthick JR; West AC; Short AK; Chuckowree J; Polanowski AM; Thomson RJ; Dickinson JL Tweet
2015	Qadi A, Taberlay PC, Phillips JL, Young A, West AC, et al., 'The leukemia inhibitory factor receptor gene is a direct target of RUNX1', Journal of Cellular Biochemistry, 117, (1) pp. 49-58. ISSN 0730-2312 (2015) [Refereed Article] DOI: 10.1002/jcb.25246 [eCite] [Details] Citations: Scopus - 6Web of Science - 5 Co-authors: Taberlay PC; Phillips JL; Young A; West AC; Brettingham-Moore KH; Dickinson JL Tweet
2014	Herbert KJ, Holloway A, Cook AL, Chin PS, Snow ET, 'Arsenic exposure disrupts epigenetic regulation of SIRT1 in human keratinocytes', Toxicology and Applied Pharmacology, 281, (1) pp. 136-145. ISSN 0041-008X (2014) [Refereed Article] DOI: 10.1016/j.taap.2014.09.012 [eCite] [Details] Citations: Scopus - 30Web of Science - 21 Co-authors: Herbert KJ; Cook AL; Chin PS; Snow ET Tweet
2014	Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, et al., 'RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization', BMC Cancer, 14 Article 808. ISSN 1471-2407 (2014) [Refereed Article] DOI: 10.1186/1471-2407-14-808 [eCite] [Details] Citations: Scopus - 26Web of Science - 25 Co-authors: Young A; Berry R; Blackburn NB; Dickinson JL; Phillips JL; Brettingham-Moore KH Tweet
2014	Zhou Y, Simpson Jr S, Holloway AF, Charlesworth J, van der Mei I, et al., 'The potential role of epigenetic modifications in the heritability of multiple sclerosis', Multiple Sclerosis Journal, 20, (2) pp. 135-140. ISSN 1352-4585 (2014) [Refereed Article] DOI: 10.1177/1352458514520911 [eCite] [Details] Citations: Scopus - 24Web of Science - 23 Co-authors: Zhou Y; Simpson Jr S; Charlesworth J; van der Mei I; Taylor BV Tweet
2013	Lim PS, Li J, Holloway AF, Rao S, 'Epigenetic regulation of inducible gene expression in the immune system', Immunology, 139, (3) pp. 285-293. ISSN 0019-2805 (2013) [Refereed Article] DOI: 10.1111/imm.12100 [eCite] [Details] Citations: Scopus - 44Web of Science - 42 Tweet
2012	Poke FS, Upcher WR, Sprod OR, Young A, Brettingham-Moore KH, et al., 'Depletion of c-Rel from cytokine gene promoters is required for chromatin reassembly and termination of gene responses to T cell activation', PLoS One, 7, (7) Article e41734. ISSN 1932-6203 (2012) [Refereed Article] DOI: 10.1371/journal.pone.0041734 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Poke FS; Sprod OR; Young A; Brettingham-Moore KH Tweet
2011	Chin SP, Dickinson JL, Holloway AF, 'Epigenetic regulation of prostate cancer', Clinical Epigenetics, 2, (2) pp. 151-169. ISSN 1868-7075 (2011) [Refereed Article] DOI: 10.1007/s13148-011-0041-7 [eCite] [Details] Citations: Scopus - 30Web of Science - 24 Co-authors: Chin SP; Dickinson JL Tweet
2011	Hale DM, Ray S, Leung JY, Holloway AF, Chung RS, et al., 'Olfactory ensheathing cells moderate nuclear factor kappaB translocation in astrocytes ', Molecular and Cellular Neuroscience, 46, (1) pp. 213-221. ISSN 1044-7431 (2011) [Refereed Article] DOI: 10.1016/j.mcn.2010.09.004 [eCite] [Details] Citations: Scopus - 11Web of Science - 10 Co-authors: Hale DM; Ray S; Leung JY; Chung RS; West AK; Chuah MI Tweet
2010	Oakford PC, James SR, Qadi A, West AC, Ray SN, et al., 'Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1', Leukemia Research, 34, (9) pp. 1203-1213. ISSN 0145-2126 (2010) [Refereed Article] DOI: 10.1016/j.leukres.2010.03.029 [eCite] [Details] Citations: Scopus - 14Web of Science - 15 Co-authors: Oakford PC; West AC; Ray SN Tweet
2010	Poke FS, Qadi A, Holloway AF, 'Reversing Aberrant Methylation Patterns in Cancer', Current Medicinal Chemistry, 17, (13) pp. 1246-1254. ISSN 0929-8673 (2010) [Refereed Article] DOI: 10.2174/092986710790936329 [eCite] [Details] Citations: Scopus - 13Web of Science - 12 Co-authors: Poke FS Tweet
2008	Brettingham-Moore KH, Sprod OR, Chen X, Oakford PC, Shannon MF, et al., 'Determinants of a transcriptionally competent environment at the GM-CSF promoter', Nucleic Acids Research, 36, (8) pp. 2639-2653. ISSN 0305-1048 (2008) [Refereed Article] DOI: 10.1093/nar/gkn117 [eCite] [Details] Citations: Scopus - 17Web of Science - 14 Co-authors: Brettingham-Moore KH; Sprod OR; Oakford PC Tweet
2007	Holloway AF, Oakford PC, 'Targeting Epigentic Modifiers in Cancer', Current Medicinal Chemistry, 14, (24) pp. 2540-2547. ISSN 0929-8673 (2007) [Refereed Article] DOI: 10.2174/092986707782023271 [eCite] [Details] Citations: Scopus - 16Web of Science - 13 Co-authors: Oakford PC Tweet
2006	Shannon MF, Chen X, Brettingham-Moore KH, Holloway AF, 'Chromatin remodelling: Distinct molecular events during differentiation and activation of T cells', Current Immunology Reviews, 2, (3) pp. 273-289. ISSN 1573-3955 (2006) [Refereed Article] DOI: 10.2174/157339506778018587 [eCite] [Details] Citations: Scopus - 1 Co-authors: Brettingham-Moore KH Tweet
2005	Brettingham-Moore KH, Rao S, Jeulich T, Shannon MF, Holloway AF, 'GM-CSF promoter chromatin remodelling and gene transcription display distinct signal and transcription factor requirements', Nucleic Acids Research, 33, (1) pp. 225-234. ISSN 0305-1048 (2005) [Refereed Article] DOI: 10.1093/nar/gki161 [eCite] [Details] Citations: Scopus - 31Web of Science - 28 Co-authors: Brettingham-Moore KH Tweet
2004	Henderson A, Holloway AF, Reeves R, Tremethick DJ, 'Recruitment of SW1/SNF to the human immunodeficiency virus type 1 promotor', Molecular and Cellular Biology, 24, (1) pp. 389-397. ISSN 0270-7306 (2004) [Refereed Article] DOI: 10.1128/MCB.24.1.389-397.2004 [eCite] [Details] Citations: Scopus - 68Web of Science - 62 Tweet
2003	Holloway AF, Rao S, Chen X, Shannon MF, 'Changes in chromatin accessibility across the GM-CSF promoter upon T cell activation are dependent on nuclear factor kappaB proteins', Journal of Experimental Medicine, 197, (4) pp. 413-423. ISSN 0022-1007 (2003) [Refereed Article] DOI: 10.1084/jem.20021039 [eCite] [Details] Citations: Scopus - 63Web of Science - 61 Tweet
2002	Chung RS, Holloway AF, Eckhardt BL, Harris JA, Vickers JC, et al., 'Sheep have an unusual variant of the brain-specific metallothionein, metallothionein-III', Biochemical Journal, 365 pp. 323-328. ISSN 0264-6021 (2002) [Refereed Article] DOI: 10.1042/BJ20011751 [eCite] [Details] Citations: Scopus - 20Web of Science - 18 Co-authors: Chung RS; Harris JA; Vickers JC; Chuah MI; West AK Tweet
2002	Holloway AF, Rao S, Shannon MF, 'Regulation of cytokine gene transcription in the immune system', Molecular Immunology, 38, (8) pp. 567-580. ISSN 0161-5890 (2002) [Refereed Article] DOI: 10.1016/S0161-5890(01)00094-3 [eCite] [Details] Citations: Scopus - 54Web of Science - 48 Tweet
2000	Holloway AF, Occhiodoro F, Mittler G, Meisterernst MF, Shannon MF, 'Functional interaction between the HIV transactivator Tat and the transcriptional coactivator PC4 in T cells', Journal of Biological Chemistry, 275, (28) pp. 21668-21677. ISSN 0021-9258 (2000) [Refereed Article] DOI: 10.1074/jbc.M909058199 [eCite] [Details] Citations: Scopus - 18Web of Science - 19 Tweet
1997	Holloway AF, Stennard FA, Dziegielewska KM, Weller WL, West AK, 'Localisation and expression of metallothionein immunoreactivity in the developing sheep brain', International Journal of Developmental Neuroscience, 15, (2) pp. 195-203. ISSN 0736-5748 (1997) [Refereed Article] DOI: 10.1016/S0736-5748(96)00091-3 [eCite] [Details] Citations: Scopus - 27Web of Science - 29 Co-authors: Stennard FA; Dziegielewska KM; Weller WL; West AK Tweet
1997	Holloway AF, Stennard FA, West AK, 'Human metallothionein gene MT1L mRNA is present in several human tissues but is unlikely to produce a metallothionein protein', FEBS Letters, 404, (1) pp. 41-44. ISSN 0014-5793 (1997) [Refereed Article] DOI: 10.1016/S0014-5793(97)00082-3 [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Stennard FA; West AK Tweet
1997	Skabo SJ, Holloway AF, West AK, Chuah MI, 'Metallothioneins 1 and 2 are expressed in the olfactory mucosa of mice in untreated animals and during the regeneration of the epithelial layer', Biochemical and Biophysical Research Communications, 232, (1) pp. 136-142. ISSN 0006-291X (1997) [Refereed Article] DOI: 10.1006/bbrc.1997.6243 [eCite] [Details] Citations: Scopus - 15Web of Science - 17 Co-authors: Skabo SJ; West AK; Chuah MI Tweet

Chapter in Book

(6 outputs)

Year	Citation	Altmetrics
2013	Chin PS, Dickinson JL, Holloway AF, 'Integrins in Prostate Cancer Invasion and Metastasis', Advances in Prostate Cancer, InTech, Gerhard Hamilton (ed), Croatia, pp. 621-640. ISBN 978-953-51-0932-7 (2013) [Research Book Chapter] DOI: 10.5772/45948 [eCite] [Details] Co-authors: Chin PS; Dickinson JL Tweet
2012	Apps LD, Holloway AF, 'The role of Chromatin in inducible gene regulation in the immune system', Histones: Class, Structure and Function, Nova Science Publishers, CH Shen (ed), New York, United States, pp. 185-200. ISBN 978-1-62100-274-1 (2012) [Research Book Chapter] [eCite] [Details] Co-authors: Apps LD Tweet
2011	Marthick JR, Holloway AF, Dickinson JL, 'Integrins as determinants of genetic susceptibility, tumour behaviour and their potential as therapeutic targets', Prostate Cancer - From Bench to Bedside, InTech, Philippe E. Spiess (ed), Rijeka, Croatia, pp. 243-266. ISBN 978-953-307-331-6 (2011) [Research Book Chapter] DOI: 10.5772/1285 [eCite] [Details] Co-authors: Marthick JR; Dickinson JL Tweet
2011	Poke FS, Holloway AF, 'Chemoprevention Targeting Epigenetic Changes in Cancer', Field Cancerization: Basic Science and Clinical Applications, Nova Science Publishers, Gabriel D. Dakubo (ed), New York, pp. 559-575. ISBN 978-1-61761-006-6 (2011) [Research Book Chapter] [eCite] [Details] Co-authors: Poke FS Tweet
2001	Shannon MF, Holloway AF, 'Chromatin remodelling and transcriptional regulation of cytokine gene transcription in T cells', Cytokines and Autoimmune Disease, Humana Press, VK Kuchroo, D Hafler, N Sarvetnick and LB Nicholson (ed), Totowa, NJ, USA, pp. 25-48. ISBN 1-59259-129-9 (2001) [Research Book Chapter] [eCite] [Details]
1999	West AK, Holloway AF, Stennard FA, Miller JM, 'Metallothionein expression in the mammalian brain', Metallothionein IV, Birkh user, CD Klaassen (ed), Boston, pp. 377-382. ISBN 0-8176-5830-0 (1999) [Research Book Chapter] [eCite] [Details] Co-authors: West AK; Stennard FA; Miller JM

Conference Publication

(19 outputs)

Year	Citation	Altmetrics
2018	Chapman J, Douglas T, Choi-Lundberg DL, Holloway AF, 'What HAPpened? Lessons learned from introducing first-year cross-campus, consolidated Human Anatomy and Physiology (HAP) units', Teaching Matters 2018, 21 November 2018, Launceston, Tasmania (2018) [Conference Extract] [eCite] [Details] Co-authors: Chapman J; Douglas T; Choi-Lundberg DL
2018	Chapman JA, Douglas T, Choi-Lundberg DL, Holloway AF, 'What HAPpened? Lessons learned from introducing flipped classroom to two first-year cross-campus, Human Anatomy and Physiology (HAP) units', ANZACA 2018, 3-5 December 2018, James Cook University, Australia (2018) [Conference Extract] [eCite] [Details] Co-authors: Chapman JA; Douglas T; Choi-Lundberg DL
2011	Chin PS, Short AK, West AC, Marthick JR, Holloway AF, et al., 'Regulation of the ITGA2 gene in prostate cancer', Lorne Cancer Conference , February, Lorne, Victoria (2011) [Conference Extract] [eCite] [Details] Co-authors: Chin PS; Short AK; West AC; Marthick JR; Dickinson JL
2009	Short AK, West AC, Patterson B, Polanowski A, Holloway AF, et al., 'Methylation of the ITGA2 promoter in Prostate Cancer', Epigenetics Conference, Melbourne, Australia (2009) [Conference Extract] [eCite] [Details] Co-authors: Short AK; West AC; Patterson B; Polanowski A; Dickinson J
2005	Brettingham-Moore KH, Ray SN, Holloway AF, 'A role for the BAF remodelling complex in GM-CSF gene regulation', ComBio 2005 Combined Conference Abstracts, 25-29 Sep 2005, Adelaide, pp. 51. (2005) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH; Ray SN
2005	Brettingham-Moore KH, Shannon MF, Holloway AF, 'GM-CSF gene activation; providing an insight into the role of BRG1 in gene regulation', Mechanisms of Eukaryotic Transcription, 31 Aug - 4 Sep 2005, pp. 44. (2005) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2005	Brettingham-Moore KH, Shannon MF, Holloway AF, 'Transcription factors and chromatin remodelers involved in activating the GM-CSF gene', The Genome Conference, 13-17 Feb 2005, Victoria, pp. 101. (2005) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2005	Oakford PC, Holloway AF, 'Regulation of gene expression by the RUNX-1 transcription factor', The Genome Conference, 13-17 Feb 2005, Victoria, pp. 108. (2005) [Conference Extract] [eCite] [Details] Co-authors: Oakford PC
2004	Brettingham-Moore KH, Holloway AF, 'A role for the NF-KB family member, Crel, in chromatin remodelling events at the GM-CSF promotor', ComBio 2004, 26-30 Sept 2004, Perth, pp. 82. (2004) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2004	Brettingham-Moore KH, Shannon MF, Holloway AF, 'GM-CSF promotor remodeling and gene transcription in response to T cell activation are distinct events', The Genome Conference, 15-19 Feb 2004, Lorne, Vic (2004) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2004	Brettingham-Moore KH, Shannon MF, Holloway AF, 'Distinct signals and factors are required for GM-CSF promotor chromatin remodelling and gene transcription', ComBio 2004, 26-30 Sept 2004, Perth, pp. 46. (2004) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2003	Brettingham-Moore KH, Rao S, Shannon MF, Holloway AF, 'Disecting the molecular events involved in activation of GM-CSF gene expression in T cells', 24th Annual Conference on the Organisation and Expression of the Genome, 16-20 Feb 2003, Lorne, Victoria, pp. Poster 1-25. ISBN 0-9585259-0-0 (2003) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2003	Brettingham-Moore KH, Shannon MF, Holloway AF, 'Defining the molecular events required for GM-CSF gene activation in T cells', ComBio 2003 Combined Conference Abstracts, 9 Sept-2 Oct 2003, pp. 161. (2003) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
2003	Juelich T, Milburn P, Holloway AF, Shannon F, 'Proteomics approach for identification of coactivators complexes interacting with transcription factors at the hGM-CSF promotor', 24th Annual Conference on the Organisation and Expression of the Genome, 16-20 Feb 2003, Lorne, Victoria, pp. Poster 1-8. ISBN 0-9585259-0-0 (2003) [Conference Extract] [eCite] [Details]
2002	Holloway AF, Rao S, Brettingham-Moore KH, Shannon MF, 'Selective remodelling of a single nucleosome precedes GM-CSF transcription in T cells', Proceedings of the Australian Society for Biochemistry and Molecular Biology, 29 September - 3 October, 2002, Sydney, pp. 4. ISSN 1328-4924 (2002) [Conference Extract] [eCite] [Details] Co-authors: Brettingham-Moore KH
1999	West AK, Holloway AF, How JD, Adlard PA, Vickers JC, 'Structure and synthesis of the neuroactive metallothionein isoform, MTIII (Growth Inhibitory Factor)', HGM'99, 27-30 March 1999, Brisbane, pp. 85. (1999) [Conference Extract] [eCite] [Details] Co-authors: West AK; Vickers JC
1997	West AK, Holloway AF, 'Metallothionein expression in the developing sheep brain', European Commission, Joint Research Centre, Geel, Belgium, pp. 35. (1997) [Conference Edited] [eCite] [Details] Co-authors: West AK
1995	Holloway AF, Stennard FA, West AK, 'Expression of mammalian metallothioneins during development', Congress of the European Developmental Biology Organisation, Toulouse, France, pp. 135. (1995) [Conference Extract] [eCite] [Details] Co-authors: Stennard FA; West AK
1995	Holloway AF, Stennard FA, West AK, 'Expression of metallothionein isoforms in mammals', Lorne Genome Conference, Lorne, Vic, pp. 1-48. (1995) [Conference Extract] [eCite] [Details] Co-authors: Stennard FA; West AK

Thesis

(1 outputs)

Year	Citation	Altmetrics
1997	Holloway AF, 'Structure and expression of mammalian metallothioneins' (1997) [PhD] [eCite] [Details]

Other Public Output

(1 outputs)

Year	Citation	Altmetrics
2003	Holloway AF, 'Research on the Apple Isle', Australian Biochemist, Australian Society for Biochemistry and Molecular Biology, Sydney, 34, 2 (2003) [Magazine Article] [eCite] [Details]

Grants & Funding

Dr Holloway has had continuous external research funding since establishing her research group at the University of Tasmania in 2002, including from NHMRC as well as other research foundations.

Funding Summary

Number of grants

Total funding

$4,009,753

Projects

Examining DNA hydroxymethylation as a radiosensitisation target in medulloblastoma (2021)$11,000

Description: Radiotherapy is frequently used in treating brain cancers such as medulloblastoma. Unfortunately, outcomes are poor for many patients. This study will investigate the potential of targeting DNA hydroxymethylation to sensitise medulloblastoma cells to radiotherapy. Aim 1 will profile levels of hydroxymethylation while Aim 2 will assess the impact of TET inhibition on response to radiotherapy.
Funding: Cancer Council of Tasmania ($11,000)
Scheme: Grant-Small
Administered By: University of Tasmania
Research Team: Brettingham-Moore KH; Taberlay PC; Holloway AF
Year: 2021

Applying innovative 'omics' technologies to identify key molecular drivers of metastatic bone tumours (2021)$14,778

Description: Once cancers have spread, they become difficult to treat and increasingly resistant to therapy. Consequently, survival rates plummet, particularly for those with bone metastases. Using cutting-edge technologies, we have identified key changes in genes that allow metastatic tumour cells to survive in bone. We aim to characterise the metastatic capabilities of these key changes and determine their value as prognostic/therapeutic targets.
Funding: Cancer Council of Tasmania ($14,778)
Scheme: Grant-Small
Administered By: University of Tasmania
Research Team: Raspin K; Dickinson JL; FitzGerald LM; Holloway AF
Year: 2021

Gaining new insights into metastatic bone tumours (2020)$24,925

Description: Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy.
Funding: Royal Hobart Hospital Research Foundation ($24,925)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; Nott LM; Liu G; FitzGerald LM; Brettingham-Moore KH; Hewitt A; Taberlay PC
Year: 2020

The impact of repeated DNA damage on the molecular profile of prostate cancer cells (2019)$23,295

Description: Many cancer patients receive fractionated/recurrent dosages of DNA damaging agents and there is some evidence that this may drive future treatment resistance and metastasis. This project will profile prostate cancer cells after repeated DNA damage via RNA-seq and EPIC arrays
Funding: Royal Hobart Hospital Research Foundation ($23,295)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Brettingham-Moore KH; Black A; Taberlay PC; Holloway AF
Year: 2019

Identifying the Underlying Genetic Drivers of IPF using Complementary Approaches (2018 - 2024)$1,481,558

Description: In the first instance the goal is to define the contribution of genetic variants to IPF in the Australian population, and we are in a unique position in Australia through our collaboration with Professor Schwartz. Our focus in this particular project is on rare genetic variation, and whilst it is likely that common variation will be similar to other mostly Caucasian populations there are likely to be differences in the rare variants in genes contributing to disease in the different populations. It is therefore important that these types of studies are performed in our population if we are going to understand the biology of disease in our patients. As discussed the identification of rare variants underpinning complex disease is proving fruitful both in understanding the biology of disease, the spectrum of clinical manifestations observed and importantly providing new potential targets for therapy.
Funding: Lung Foundation Australia ($1,481,558)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Corte T; Holloway AF; Charlesworth JC; Walters EH; Wood-Baker R
Period: 2018 - 2024

A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania (2018)$22,146

Description: We propose to build upon the clinically-focused Prostate Cancer Outcomes Registry, Tasmania (PCOR-TAS) and collect matched biological samples to create a valuable resource for both clinicians and scientists. The availability of clinical and genetic data will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies.
Funding: Royal Hobart Hospital Research Foundation ($22,146)
Scheme: Grant-Minor Project
Administered By: University of Tasmania
Research Team: FitzGerald LM; Dickinson JL; Skala M; Stokes BC; Donovan S; Malley RC; Redwig F; Holloway AF; Taberlay PC
Year: 2018

Mapping epigenomic information in a three-dimensional prostate cancer cell environment (2017)$20,990

Description: We lack a model that better replicates in vivo tumour development to study epigenomic mechanisms of prostate cancer. To date, epigenetic changes in cancer have been investigated in homogenous cell lines from two-dimensional laboratory cultures or end-point tumour samples (static) from patients. Without doubt these studies have provided great insight into epigenetic differences that distinguish cancer cells from normal cells. However, there is a glaring lack of information about dynamic and temporal changes to the epigenome and cell behaviour as the cells acquire invasive potential. This is not possible using currently available two-dimensional models and clinical samples. We will address this deficit by establishing a three-dimensional model of prostate cancer that allows us to map how epigenomes and cell behaviours change during cancer development.
Funding: Cancer Council of Tasmania ($20,990)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Taberlay PC; Brettingham-Moore KH; Holloway AF; Biro M
Year: 2017

Developing CRISPR/Cas Library Screens for identifying Novel Cancer Therapies (2017)$63,845

Description: Our understanding of many cancers has improved dramatically over the past decade predominantly due to our ability to sequence entire genomes, at scale. Yet, we still require a better understanding of the underlying mechanisms that initiate and perpetuate cancers, as well as gene-based factors that initiate the transition from indolent to aggressive cancers with a propensity to metastasize. CRISPR/Cas is proving a robust, powerful and necessary tool in the laboratory that will undoubtedly underpin the next breakthrough in the field of cancer. As such, it is essential that we develop this capability at the University of Tasmania in a timely manner.The specific AIMS of this proposal are to:Aim 1: Establish CRISPR/Cas screening at the University of Tasmania as a tool to identify genesthat drive aggressive and metastatic cancers.Aim 2: Perform a genome-wide CRISPR/Cas negative selection (loss-of-function) screen toidentify genes essential for proliferation and survival, as well as metastatic behaviour.
Funding: University of Tasmania Foundation Inc ($63,845)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Taberlay PC; Hewitt A; Holloway AF; Liu G; Dickinson JL; Brettingham-Moore KH; Fitzgerald L; Eri RD; Cook AL
Year: 2017

David Collins Leukaemia Foundation Elite Research Scholarship - Epigenetic and Transcriptional regulation of leukaemia (2016 - 2019)$153,000

Description: This project will investigate how epigenetic and transcription factors co-operate to control gene expression, how this is reprogrammed in leukaemia and how epigenetic drugs impact these gene expression programs.
Funding: David Collins Leukaemia Foundation ($153,000)
Scheme: Donation - Individual
Administered By: University of Tasmania
Research Team: Holloway AF; Dickinson JL; Brettingham-Moore KH
Period: 2016 - 2019

Molecular profiling of the post radiotherapy chromatin landscape in prostate cancer cells (2016)$33,000

Description: This project will investigate the basal and post radiotherapy epigenetic changes in prostate cancer cells with divergent response to radiotherapy (RT). It will validate methylation data obtained from illumina Infinium 450 beadchip arrays, profile histone modifications post RT and investigate DNA damage post RT in cells treated with inhibitors of epigenetic enzymes (DNMT and HDAC).
Funding: Cancer Council of Tasmania ($33,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Brettingham-Moore KH; Ambrose M; Holloway AF; Skala M; Taberlay PC
Year: 2016

Exploring the mechanisms responsible for the early transformation from chronic colitis to colorectal cancer (2016)$28,000

Description: This project will be the first study to model early changes in inflammation-associated colitis without the need for carcinogentreatment, which mirrors the clinical situation of human colitis. The project will study the histological and biochemical changes associated with the development of colorectal cancer in this mouse model that closely resembles the development seen in humans. The project will also investigate the mirobiome changes in the progression.
Funding: Cancer Council of Tasmania ($28,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Kunde DA; Eri RD; Holloway AF
Year: 2016

Bi-functional opioids as a novel cancer treatment (2015)$6,567

Description: The aim of our study is to assess the anticancer effect of our 10 novel opioid drugs in six different intestinal cancer cell lines and compare them with oxaliplatin and irinotecan. The particular objectives of the study are:1. To evaluate the effect of our novel drugs on intestinal cancer cell viability, growth, proliferation and ability to form colonies.2. To explore the molecular mechanisms of the anticancer activity of our novel drugs.
Funding: Cancer Council of Tasmania ($6,567)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dietis ND; Liu J; Holloway AF; Guven N
Year: 2015

Epigenetic regulation of inegrin beta 4 as a predictor of prostate cancer progression (2015)$14,750

Description: Prostate cancer diagnoses continue to rise rapidly in Australia, but of most concern is ourcurrent inability to distinguish aggressive tumours with propensity to metastasize from moreindolent disease. This results in unnecessary treatment of many men whose cancer may neverprogress to clinically significant disease. However, progression of the disease results in aggressive, metastatic tumours which are difficult to treat and are associated with poor prognosis. We thus urgently require a better understanding of the underlying drivers of this disease, and particularly the factors and mechanisms that drive the transition to more aggressive tumours with a propensity to spread. These factors may represent biomarkers and potential therapeutic targets in prostate cancer progression.The aims of this study are therefore:1.To determine whether epigenetic changes at the ITGB4 gene are associated with its increased expression in prostate cancer progression, and 2. To investigate whether epigenetic changes at the ITGB4 gene in prostate cancer are driven by the RUNX transcription factors.
Funding: Cancer Council of Tasmania ($14,750)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Holloway AF; Dickinson JL; Brettingham-Moore KH; Rao S; Black A
Year: 2015

Embedding the benefits of undergraduate research experiences for medical research and health professional students (2015)$30,000

Description: The purpose of the project is to improve expectations and outcomes of research experiences in undergraduate medical research and health professional students.The project team will analyse the student responses, comparing theseto existing TREASURE data and evaluating student perceptions andlearning1, 2. Our improved understanding of how students perceiveresearch in the context of the health professions will be used todevelop scaffolded approaches to undergraduate research, to betterinform student expectations and better prepare students forundergraduate research experiences.
Funding: Office for Learning & Teaching ($30,000)
Scheme: Grant-Extension Funding
Administered By: University of Tasmania
Research Team: Holloway AF; Williams A-MM; Radford JC; Ogden K; Clegg L; Howitt S
Year: 2015

Familial Haematological Malignancies: understanding the role of inherited causative factors (2014)$20,000

Description: Genetic factors are known to contribute to the risk of developing haematological malignancies, however to date the underlying genetic drivers of disease development remain largely unknown. Knowing the causative genes is not only important in understanding the disease process but also provides a range of benefits in the diagnosis, development of tailored treatments, and identification of new targets for therapy. Studying families with multiple cases of these diseases is a powerful approach used to identify the causative genes.
Funding: Cancer Council of Tasmania ($20,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Charlesworth JC; Foote SJ; Thomson RJ; Holloway AF; Lowenthal RM
Year: 2014

Intersection of RUNX and integrin families in leukaemia (2014 - 2015)$30,000

Funding: David Collins Leukaemia Foundation ($30,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF; Dickinson JL
Period: 2014 - 2015

The role of epigenetic changes in the progression of clinical disease in Multiple Endocrine Neoplasia Type 1 (MEN 1) (2013)$22,500

Funding: Royal Hobart Hospital Research Foundation ($22,500)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Burgess JR; Prentice L; Holloway AF; Dickinson JL
Year: 2013

Combining deep sequencing and linkage approaches to identify rare variants contributing to familial prostate cancers (2013 - 2014)$35,000

Funding: Cancer Council of Tasmania ($35,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Thomson RJ; Charlesworth JC; Holloway AF; Jarman SN
Period: 2013 - 2014

Regulation of integrins by RUNX1 in leukaemia (2013)$30,000

Funding: David Collins Leukaemia Foundation ($30,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF; Dickinson JL; Brettingham-Moore KH
Year: 2013

Regulation of Integrin Gene Expression Programs by RUNX in Cancer (2013 - 2016)$26,250

Description: The incidence of leukaemia continues to increase in Tasmania despite advances in our understanding and treatment of the disease. A gene which is often disrupted in leukaemia is a master regulator called RUNX1, which controls how and when other genes are switched on in blood cells. This project hypothesises that RUNX1 controls cell surface molecules called integrins. It proposes that disruption of RUNX1 in blood cells leads to the development of leukaemia by altering the integrins on the surface of the cells.
Funding: Cancer Council of Tasmania ($26,250)
Scheme: Scholarship-PhD Top-Up Grant
Administered By: University of Tasmania
Research Team: Holloway AF; Dickinson JL
Period: 2013 - 2016

Regulation of gene expression in cancer (2012 - 2013)$4,500

Funding: Donation via University of Tasmania Foundation ($4,500)
Scheme: Donation - Individual
Administered By: University of Tasmania
Research Team: Holloway AF
Period: 2012 - 2013

Prostate cancer risk variants in integrin genes & their role in prostate cancer development (2012)$49,362

Funding: Cancer Council of Tasmania ($49,362)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; McMorran BJ; Thomson RJ
Year: 2012

Epigenetic regulation of T-cell gene expression programs (2012)$8,505

Funding: The Select Foundation ($8,505)
Scheme: Grant-Small Grants Scheme
Administered By: University of Tasmania
Research Team: Holloway AF; Korner H
Year: 2012

Epigenetic Regulation of Tumour Supressors in Skin Cancer (2012)$22,300

Funding: Cancer Council of Tasmania ($22,300)
Scheme: Grant-Small
Administered By: University of Tasmania
Research Team: Cook AL; Snow ET; Holloway AF
Year: 2012

Epigenomics of familial prostate cancer (2011)$14,000

Funding: Cancer Council of Tasmania ($14,000)
Scheme: Grant-Small
Administered By: University of Tasmania
Research Team: Charlesworth JC; Holloway AF; Dickinson JL
Year: 2011

Prostate cancer risk variants in integrin genes and their role in tumour development (2011)$10,000

Funding: Cancer Council of Tasmania ($10,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; McMorran BJ; Patterson B; Thomson RJ
Year: 2011

Epigenetic Regulation of the integrin, ITGA2, in Tumour Development (2011)$10,000

Funding: Cancer Council of Tasmania ($10,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF
Year: 2011

Transcriptome analysis for predicting response to radiotherapy in prostate cancer patients (2011)$9,091

Funding: Royal Hobart Hospital Research Foundation ($9,091)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Brettingham-Moore KH; Skala M; Holloway AF; Stankovich J
Year: 2011

Regulation of the LIFR Receptor by RUNX1 (2011)$49,500

Funding: David Collins Leukaemia Foundation ($49,500)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF; Tegg EM
Year: 2011

Rising Stars 3 (2011 - 2013)$51,000

Funding: University of Tasmania ($51,000)
Scheme: Grant-Rising Stars Round 3
Administered By: University of Tasmania
Research Team: Holloway AF
Period: 2011 - 2013

Upgrade of the flow cytometry facility of the Menzies Research Institute with a multi-parameter analytical flow cytometer CyAn ADP 9 Color for key applications (2011)$75,000

Funding: Clive & Vera Ramaciotti Foundation ($75,000)
Scheme: Grant-Equipment
Administered By: University of Tasmania
Research Team: Korner H; McMorran BJ; Woods GM; Holloway AF; West AK
Year: 2011

ITGA2: characterisation as a potential biomarker in prostate cancer (2010)$48,125

Funding: Cancer Council of Tasmania ($48,125)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; Patterson B; Stankovich J; McMorran BJ
Year: 2010

Regulation of the Leukaemia Inhibitory Factor Receptor complex by RUNX1 (2010)$48,950

Funding: David Collins Leukaemia Foundation ($48,950)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF
Year: 2010

Elucidation of the role of the integrin alpha 2 gene (ITGA2) in prostate cancer (2009)$45,600

Funding: Cancer Council of Tasmania ($45,600)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; Patterson B; Stankovich J; McMorran BJ
Year: 2009

Investigating novel targets of the RUNX1 transcription factor (2009)$10,000

Funding: David Collins Leukaemia Foundation ($10,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF
Year: 2009

Elucidation of the role of a novel susceptibility gene in prostate cancer (2008)$25,000

Funding: Cancer Council of Tasmania ($25,000)
Scheme: Grant-Cancer Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; Patterson B; McMorran BJ; Stankovich J
Year: 2008

Elucidation of the role of a novel susceptibility gene in prostate cancer (2008)$25,000

Funding: Royal Hobart Hospital Research Foundation ($25,000)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Dickinson JL; Holloway AF; Patterson B; McMorran BJ; Stankovich J
Year: 2008

Characterising aberrant RUNX1 transcriptional complexes (2008)$20,000

Funding: David Collins Leukaemia Foundation ($20,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF
Year: 2008

How does basal chromatin structure predict cytokine gene responses (2008 - 2010)$501,000

Funding: National Health & Medical Research Council ($501,000)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Holloway AF; Shannon MF
Period: 2008 - 2010
Grant Reference: 490014

Scarring and angiogenesis in the airway wall in smoking and COPD: links between inflammation and remodelling (2008 - 2010)$347,125

Funding: National Health & Medical Research Council ($347,125)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Walters EH; Wood-Baker R; Reid DW; Muller HK; Holloway AF
Period: 2008 - 2010
Grant Reference: 490023

Silencing the AML1/ETO fusion gene as a treatment strategy for acute myeloid leukaemia (2008)$7,704

Funding: Clifford Craig Foundation ($7,704)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Woods GM; Holloway AF; Casey NP
Year: 2008

Deregulation of Gene Expression by RUNX1 Fusion Proteins in Leukaemia (2007)$25,000

Funding: David Collins Leukaemia Foundation ($25,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF
Year: 2007

Switching genes on in immune cells: how does basal chromatin structure predict cytokine gene responses? (2007)$20,000

Funding: Royal Hobart Hospital Research Foundation ($20,000)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Holloway AF; Shannon MF; Walters EH
Year: 2007

EMBO Conference on Chromatin and Epigenetics attendance (2007)$1,200

Funding: Cancer Council of Tasmania ($1,200)
Scheme: Grant-Travel
Administered By: University of Tasmania
Research Team: Holloway AF; Taberlay PC
Year: 2007

Philippa Oakford: Epigenetics 2007 Australian Scientific Conference (2007)$400

Funding: David Collins Leukaemia Foundation ($400)
Scheme: Award-Professional Development
Administered By: University of Tasmania
Research Team: Holloway AF; Taberlay PC
Year: 2007

Investigating the Role of the RUNX1 Protein in the Regulation of Gene Expression in Myeloid Cells (2006)$25,000

Funding: David Collins Leukaemia Foundation ($25,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF
Year: 2006

Luminometry System (2006)$22,300

Funding: National Health & Medical Research Council ($22,300)
Scheme: Grant-Equipment
Administered By: University of Tasmania
Research Team: Holloway AF; West AK; Chung RS
Year: 2006
Grant Reference: 361670

Leica DMIRB Inverted Microscope Configured for Fluorescence and Bright Field with Phase Contrast (2005)$10,000

Funding: National Health & Medical Research Council ($10,000)
Scheme: Grant-Equipment
Administered By: University of Tasmania
Research Team: Chuah MI; West AK; Holloway AF; Rattigan S; Richards SM; Chung RS; Foa LC
Year: 2005
Grant Reference: 264668

Identifying Genes Regulated by AML1 in Myeloid Cells (2005)$28,000

Funding: David Collins Leukaemia Foundation ($28,000)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF; Rao S
Year: 2005

Role of NF-kB Remodelling Complexes in Inducible Gene Expression in T Cells (2004 - 2006)$239,750

Funding: National Health & Medical Research Council ($239,750)
Scheme: Grant-Project Three Year
Administered By: University of Tasmania
Research Team: Holloway AF; Shannon MF
Period: 2004 - 2006
Grant Reference: 302202

Regulation of Gene Expression by the AML1 Transcription Factor in Myeloid Cells (2004)$28,380

Funding: David Collins Leukaemia Foundation ($28,380)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Holloway AF
Year: 2004

Refrigerated Benchtop Centrifuge (2004)$12,941

Funding: National Health & Medical Research Council ($12,941)
Scheme: Grant-Equipment
Administered By: University of Tasmania
Research Team: Holloway AF; West AK; Chuah MI; Rattigan S; Richards SM
Year: 2004
Grant Reference: 264536

Development of a Screen for AML1 Target Genes (2003)$8,416

Funding: Royal Hobart Hospital Research Foundation ($8,416)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Holloway AF; Ragg SJ
Year: 2003

A Functional Proteomics Approach to the Study of Inducible Gene Transcription in a Chromatin Context (2002 - 2004)$115,000

Funding: National Health & Medical Research Council ($115,000)
Scheme: Grant-Project
Administered By: Australian National University
Research Team: Shannon MF; Holloway AF
Period: 2002 - 2004

Research Supervision

Dr Holloway has extensive experience as a supervisor of PhD and Honours students, with her completed PhD students going on to undertake postdoctoral studies in highly successful research groups in Australia, USA and UK.

Current

Completed

Current

Degree	Title	Commenced
PhD	Epigenetic Regulation of Integrin ITGA2 and the Identification of Epigenetic Drivers of Bone Metastasis in Breast Cancer	2018
PhD	Leadership Development: Understanding the missing link in Health and Human Services workforce development	2020
PhD	Epigenetic Evolution During Cancer Treatment	2020

Completed

Degree	Title	Completed
PhD	Epigenetic Mechanisms in Prostate Cancer Metastasis to the Bone Candidate: Emma Jane Wilkinson	2021
PhD	Transcriptomic and DNA Methylation Alterations in Prostate Cancer Metastasis Candidate: Aparna Shree Raina	2021
PhD	Gene Regulation by RUNX1 in the Absence of Consensus Sequences Candidate: Alexandra Morgan Woodworth	2020
PhD	Using Families to Understand the Impact of Genetic Variation on Prostate Cancer Candidate: Kelsie Raspin	2020
PhD	Regulation of ITGA6 and ITGB4 Integrin Genes by RUNX1 and Epigenetic Mechanisms Candidate: Jessica Louise Phillips	2017
PhD	Epigenomic and Genomic Analysis of Familial Prostate Cancer Candidate: Emma Cazaly	2017
PhD	The Anti-Cancer Activity of the Natural Product, Fucoidan, in Haematological Malignancies Candidate: Farzaneh Atashrazm	2016
PhD	Molecular Mechanisms Used by Staphylococcus Aureus to Access Iron from Human Haemoglobin Candidate: Claire Frances Dickson	2014
PhD	Epigenetic mechanisms of arsenic-induced transformation in human keratinocytes Candidate: Katharine Jane Herbert	2014
PhD	Regulation of the ITGA2 Gene in Prostate Cancer Candidate: Suyin Paulynn Chin	2014
PhD	Regulation of Inducible Immune Gene Expression in T Cells Compared to Macrophages Candidate: Lucy Damaris Apps	2014
PhD	Regulation of the LIFR and gp130 Genes by the RUNX1 Transcription Factor Candidate: Abeer Ahmed Qadi	2012
PhD	Differential Expression of the GM-CSF Gene in the Immune System is Regulated By Epigenetic Factors Candidate: Owen Ralph Sprod	2011
PhD	Regulation of Gene Expression by the RUNX1 Transcription Factor Candidate: Phillippa Claire Oakford	2008
PhD	Defining the Molecular Events Required for GM-CSF Gene Activation in T Cells Candidate: Kate Brettingham-Moore	2006